Search clinical trials for: 101-PGC-005

Total 9427 results

101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
101 Therapeutics

Terminated

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

COVID-19

Israel
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
Cardix Therapeutics LLC

Not yet recruiting

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Bradycardia
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Autotelicbio

Recruiting

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Diabetes Mellitus, Type 2 | Essential Hypertension

Korea, Republic of
Hoth Therapeutics, Inc.
Worldwide Clinical Trials

Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)

Acneiform Eruption Due to Chemical | Xerosis Cutis | Paronychia

United States
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
King's College London
Guy's and St Thomas' NHS Foundation Trust

Recruiting

Preimplantation Genetic Screening in IVF Treatment (PGSINIVF)

Infertility

United Kingdom
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
Pfizer

Terminated

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

United States, Spain, France, Japan, New Zealand, Belgium, Portugal, Netherlands, Argentina, United Kingdom, Australia, Slovakia, Poland, Chile, Finland, Italy, South Africa, Sweden, Switzerland
101 Therapeutics

Active, not recruiting

101-PGC-005 for the Treatment of COVID-19

COVID-19

India
Genomic Prediction Inc.

Recruiting

Preimplantation Genetic Testing in Women of Advanced Maternal Age (GETSET)

Infertility, Female

United States
Reprogenetics

Suspended

Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age

Infertility

United States, Spain
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
Toll Biotech Co. Ltd. (Beijing)

Recruiting

A Study of Single and Multiple Oral Doses of TollB-001

Rheumatoid Arthritis

China
IntegoGen, LLC

Withdrawn

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
BioLite, Inc.

Completed

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Major Depressive Disorder

Taiwan, United States
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
Pfizer

Terminated

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

Australia, France, Finland, Portugal, Spain, United Kingdom, Poland, Japan, Italy, Belgium, Switzerland, Netherlands, Chile, Slovakia, Sweden, New Zealand, South Africa
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Northwell Health
Genomind, LLC

Completed

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Bipolar Disorder

United States
Click Therapeutics, Inc.

Active, not recruiting

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Psoriasis | Atopic Dermatitis

United States
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Legacy Health System

Unknown

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

Menopause | Climacteric; Menorrhagia, Menopausal

United States
JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
Frontera Therapeutics

Recruiting

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

China
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China

Search clinical trials for: 101-PGC-005

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations